Inventiva and Novalix have entered into a strategic alliance to discover the clinical candidates, targeting nuclear receptors.
As part of the agreement, Inventiva and NovAliX offer pharmaceutical and biotech companies a set of fully integrated nuclear receptor drug discovery capabilities.
The collaboration will use both the companies's diversified proprietary libraries in combination with complementary screening technologies.
Inventiva co-founder and CSO Pierre Broqua said, "Based on our unique drug-discovery platform, proven track record in nuclear receptors, and our experience in managing collaborations, I strongly believe in our ability to again deliver innovative drug development candidates to our partners."
The alliance will allow pharmaceutical and biotech companies to entrust their entire nuclear receptor drug discovery program from target validation to IND stage to one single experienced partner.
Novalix CEO Denis Zeyer said ten years past, they built the company on the academic legacy of Pierre Chambon and Dino Moras, world class scientists, who pioneered the field of structural biology and nuclear receptors.
"We have turned that academic excellence into promising pharmaceutical candidates and this alliance is the opportunity to further extend that success," Zeyer added.